Date post: | 14-Jun-2015 |
Category: |
Documents |
Upload: | orna-porat-berger |
View: | 107 times |
Download: | 0 times |
1
Teva introduction
2013
Established by three young pharmacists, selling drugs in a small store
Starting out at 1901 in Jerusalem
More than a century later
We are among the top 10 pharmaceutical companies and a world leader in Generics
Our Vision
Being the most indispensable
medicines company for the world,
executing on our obligation to
our patients, customers,
shareholders and employees
We have Profound Foundations
45,000 employees
73 manufacturing
sites
111 years in
existence
1,000 molecules
60 countries
73B tablets and
capsules per annum
55,000+ SKUs
$5.01 2013 EPS
$20.3B 2013 revenues
Core Strengths
Leading healthcare provider
Balanced business
model
Integrated
R&D
Manufacturing strengths
Partnering experience
Go-to-market capabilities
Entrepreneurial employees and
culture
Growth drivers
CNS Respiratory High-value generics NTEs (New therapeutic entity)
MS PD Oncology Respiratory Women’s Health Branded generics High-value generics
OTC (over the counter)
MS Branded generics
Branded generics Respiratory Women’s Health MS OTC (over the counter)
MS Generics Branded generics
A truly global operations network
Financial Growth
2013 2012
20,314 20,317 Sales $M
5,198 5,715 Operating Income $M
4,255 4,671 Net Income $M
* Operating income and net income are non-GAAP results
Expansion of wealth and health care access
Rising health care costs
Our World Changes
Aging population
Increasing competition in generics
Shift in disease patterns
Rising bar for product innovation
Complicated, expanding global market
Complexity
Cost
Network footprint
Commodity
The new Teva
Less More
Globalized
Valuable pipeline
Sustainable products
Patient and customer focus
Balanced profits
Shareholder value
Teva 2017: a reshaped company
Sector leadership in all areas
Sustainable profitable growth
Present in all major markets
Consistent shareholder value creation
Successful alliances
Rich Pipeline
Branded generics business
R&D capabilities
Impact healthcare system
Pipeline of high-value products
Generics: a great future
Global
Sustainable high-barrier to entry
Rapid growth
Dramatically enhanced in selected areas
Research and development
Develop the most competitive
and focused pipeline
to address unmet patient needs
in a highly differentiated way
to drive the growth of Teva
Life and science intimately connected … that’s uniquely Teva
NTEs High value
generics
Focused specialty portfolio
NTEs - The Future of Teva R&D
NEW THERAPEUTIC ENTITY Known molecule that is formulated, delivered, or used in a novel way to
address specific patient needs
Specialty medicines: focus and build leadership
CNS
Respiratory
New Therapeutic Entities (NTEs)
Oncology, Women's Health, Biologics
Protect and expand MS franchise
Build products and pipeline
Invest in capabilities and pipeline
Continue global expansion
Capitalize on unique Teva interface
of Generics and Specialty
Selectively invest
17 17
OTC Business
World’s leading provider of medicines Portfolio of leading brands
Best-in-class
Consumer understanding
Brand-building
Advertising scale
Strong product development and
production capabilities World’s leading brand-
builder
+
PGT Consumer Healthcare: JV with P&G leverages value in existing OTC business
18
Our Guiding Values
Our Guiding Values represent an unbreakable chain of behaviors ...
and a process that embodies the very nature of how we operate …
at the heart of Teva.
19
Our Storyline
At the heart of Teva, we believe that:
Individual Integrity drives mutual Respect …
Mutual Respect leads to healthy Collaboration …
Healthy Collaboration powers our pursuit of Excellence …
Our pursuit of Excellence is key to Teva’s ongoing Leadership …
… and ongoing Leadership depends upon our individual Integrity.
20